These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21506636)

  • 1. TLR-7 and -8 agonists as vaccine adjuvants.
    Tomai MA; Vasilakos JP
    Expert Rev Vaccines; 2011 Apr; 10(4):405-7. PubMed ID: 21506636
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
    Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
    Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
    Dowling DJ
    Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
    Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
    J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.
    Lan T; Putta MR; Wang D; Dai M; Yu D; Kandimalla ER; Agrawal S
    Biochem Biophys Res Commun; 2009 Aug; 386(3):443-8. PubMed ID: 19523922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, purification, and characterization of oligoribonucleotides that act as agonists of TLR7 and/or TLR8.
    Lan T; Kandimalla ER
    Methods Mol Biol; 2011; 764():249-61. PubMed ID: 21748646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic agonists of Toll-like receptors 7, 8 and 9.
    Agrawal S; Kandimalla ER
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
    Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
    Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New adjuvants for human vaccines.
    Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
    Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical resiquimod promotes priming of CTL to parenteral antigens.
    Chang BA; Cross JL; Najar HM; Dutz JP
    Vaccine; 2009 Sep; 27(42):5791-9. PubMed ID: 19660592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
    Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
    Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor ligands energize peptide vaccines through multiple paths.
    Celis E
    Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination.
    Xia H; Qin M; Wang Z; Wang Y; Chen B; Wan F; Tang M; Pan X; Yang Y; Liu J; Zhao R; Zhang Q; Wang Y
    Nano Lett; 2022 Apr; 22(7):2978-2987. PubMed ID: 35302770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction.
    Lynn GM; Chytil P; Francica JR; Lagová A; Kueberuwa G; Ishizuka AS; Zaidi N; Ramirez-Valdez RA; Blobel NJ; Baharom F; Leal J; Wang AQ; Gerner MY; Etrych T; Ulbrich K; Seymour LW; Seder RA; Laga R
    Biomacromolecules; 2019 Feb; 20(2):854-870. PubMed ID: 30608149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
    Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
    J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use.
    Rizza P; Capone I; Moretti F; Proietti E; Belardelli F
    Expert Rev Vaccines; 2011 Apr; 10(4):487-98. PubMed ID: 21506646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
    McGowan DC; Herschke F; Khamlichi MD; Rosauro ML; Benedicto SMP; Pauwels F; Stoops B; Pande V; Scholliers A; Van Schoubroeck B; Mostmans W; Van Dijck K; Thoné T; Horton H; Fanning G; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3216-3221. PubMed ID: 30143425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic Acid Conjugates of TLR7/8 Agonists for Targeted Delivery to Secondary Lymphoid Tissue.
    Yoo E; Salyer ACD; Brush MJH; Li Y; Trautman KL; Shukla NM; De Beuckelaer A; Lienenklaus S; Deswarte K; Lambrecht BN; De Geest BG; David SA
    Bioconjug Chem; 2018 Aug; 29(8):2741-2754. PubMed ID: 29969553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.